

Peter L Anderson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11366617/publications.pdf>

Version: 2024-02-01

192
papers

13,847
citations

36303

51
h-index

22832

112
g-index

195
all docs

195
docs citations

195
times ranked

8140
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. <i>Journal of Infectious Diseases</i> , 2022, 225, 1741-1749.	4.0	35
2	OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	3.0	0
3	Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa. <i>Aids</i> , 2022, 36, 933-940.	2.2	15
4	Tenofovir Diphosphate in Dried Blood Spots in Pregnant and Postpartum Women With HIV in Kenya: A Novel Approach to Measuring Peripartum Adherence. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 310-317.	2.1	1
5	Miniature mass spectrometer-based point-of-care assay for cabotegravir and rilpivirine in whole blood. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 3387-3395.	3.7	11
6	Development and Evaluation of Nanoparticles-in-Film Technology to Achieve Extended In Vivo Exposure of MK-2048 for HIV Prevention. <i>Polymers</i> , 2022, 14, 1196.	4.5	3
7	Genital Inflammation Is Not Associated With Decreased Vaginal Tenofovir Concentrations in Women Taking Oral PrEP. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 390-395.	2.1	1
8	Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. <i>Lancet, The</i> , 2022, 399, 1779-1789.	13.7	177
9	Understanding Pre-Exposure Prophylaxis Adherence in Young Women in Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 251-260.	2.1	12
10	Intimate partner violence and oral HIV pre-exposure prophylaxis adherence among young African women. <i>Aids</i> , 2022, 36, 1151-1159.	2.2	8
11	The use of technology-based adherence monitoring in the treatment of hepatitis C virus. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612210956.	1.8	2
12	Usability and effectiveness of adherence monitoring of a mobile app designed to monitor and improve adherence to event-driven and daily HIV pre-exposure prophylaxis among men who have sex with men in Taiwan. <i>Digital Health</i> , 2022, 8, 205520762211027.	1.8	1
13	Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 939-943.	1.1	4
14	PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project. <i>Journal of the International AIDS Society</i> , 2022, 25, .	3.0	29
15	Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2117-e2123.	5.8	33
16	Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa. <i>Clinical Infectious Diseases</i> , 2021, 73, e1893-e1900.	5.8	35
17	Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2021, 72, 2025-2028.	5.8	4
18	Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 421-428.	1.1	12

#	ARTICLE	IF	CITATIONS
19	Higher medication complexity in persons with HIV is associated with lower tenofovir diphosphate in dried blood spots. <i>Pharmacotherapy</i> , 2021, 41, 291-298.	2.6	1
20	Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 73-80.	2.1	6
21	Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial. <i>Lancet HIV</i> , 2021, 8, e130-e137.	4.7	41
22	Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, 1149-1156.	5.8	15
23	A Descriptive Analysis of Dried Blood Spot Adherence Testing Among Ugandans with HIV Presenting with Cryptococcal Meningitis. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 529-533.	1.1	1
24	Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab200.	0.9	9
25	Improving adherence to daily preexposure prophylaxis among MSM in Amsterdam by providing feedback via a mobile application. <i>Aids</i> , 2021, 35, 1823-1834.	2.2	7
26	Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP. <i>Journal of the International AIDS Society</i> , 2021, 24, e25708.	3.0	19
27	Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 671-679.	2.1	16
28	Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background HIV incidence: a secondary analysis of a randomized, controlled trial. <i>Journal of the International AIDS Society</i> , 2021, 24, e25744.	3.0	12
29	A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 655-669.	1.8	1
30	PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. <i>PLoS Medicine</i> , 2021, 18, e1003670.	8.4	87
31	Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence. <i>Aids</i> , 2021, 35, 1949-1956.	2.2	8
32	Assessing longitudinal patterns of depressive symptoms and the influence of symptom trajectories on HIV pre-exposure prophylaxis adherence among adolescent girls in the HPTN 082 randomized controlled trial. <i>Journal of the International AIDS Society</i> , 2021, 24, e25731.	3.0	17
33	Letter to the Editor: Revisiting the Pharmacological Forgiveness of HIV Pre-Exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 407-408.	1.1	1
34	The Magnetic Couples Study: protocol for a mixed methods prospective cohort study of HIV-serodifferent heterosexual couples' perspectives and use of pre-exposure prophylaxis (PrEP). <i>BMJ Open</i> , 2021, 11, e048993.	1.9	3
35	Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2675-2680.	3.0	6
36	Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. <i>Aids</i> , 2021, 35, 2481-2487.	2.2	8

#	ARTICLE	IF	CITATIONS
37	Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIV. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab463.	0.9	13
38	Beyond HIV viral load: application of pharmacologic measures to identify ART adherence mismatch. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 2049936121110105.	1.8	4
39	Preventive Efficacy of a Tenofovir Alafenamide Fumarate Nanofluidic Implant in SHIV-Challenged Nonhuman Primates. <i>Advanced Therapeutics</i> , 2021, 4, 2000163.	3.2	28
40	Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa564.	0.9	14
41	Associations Between Tenofovir Diphosphate in Dried Blood Spots, Impaired Physical Function, and Fracture Risk. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa577.	0.9	2
42	Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case-control cohort study. <i>Journal of the International AIDS Society</i> , 2021, 24, e25849.	3.0	5
43	Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113. <i>Clinical Infectious Diseases</i> , 2020, 70, 687-691.	5.8	22
44	Short Communication: Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 173-175.	1.1	4
45	Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for On-Demand HIV Preexposure Prophylaxis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1200-1208.	4.7	3
46	Direct quantitation of tenofovir diphosphate in human blood with mass spectrometry for adherence monitoring. <i>Analytical and Bioanalytical Chemistry</i> , 2020, 412, 1243-1249.	3.7	17
47	Income Inequality Is Associated With Low Cumulative Antiretroviral Adherence in Persons With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa391.	0.9	4
48	Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2020, 396, 239-254.	13.7	245
49	HIV Pre-Exposure Prophylaxis for Conception Among HIV Serodiscordant Couples in the United States: A Cohort Study. <i>AIDS Patient Care and STDs</i> , 2020, 34, 295-302.	2.5	5
50	Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant. <i>Pharmaceutics</i> , 2020, 12, 981.	4.5	13
51	Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3303-3310.	3.0	9
52	Factors associated with tenofovir diphosphate concentrations in dried blood spots in persons living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1591-1598.	3.0	14
53	Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 323-330.	2.1	26
54	Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion. <i>International Journal of Infectious Diseases</i> , 2020, 94, 41-43.	3.3	9

#	ARTICLE	IF	CITATIONS
55	Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications. <i>International Journal of Pharmaceutics</i> , 2020, 587, 119623.	5.2	10
56	Frequency and Predictors of Tenofovir-diphosphate Detection Among Young Kenyan Women in a Real-world Pre-exposure Prophylaxis Implementation Program. <i>Clinical Infectious Diseases</i> , 2020, 71, e509-e512.	5.8	13
57	Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 463-474.	3.3	23
58	Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions. <i>Current HIV/AIDS Reports</i> , 2020, 17, 301-314.	3.1	83
59	Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes Mellitus. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 483-488.	2.1	4
60	Editorial: Pharmacokinetics and Pharmacodynamics of Pre-Exposure Prophylaxis Against HIV. <i>Frontiers in Pharmacology</i> , 2020, 11, 1288.	3.5	0
61	Pharmacokinetic and Pharmacodynamic Properties of Metronidazole in Pediatric Patients With Acute Appendicitis: A Prospective Study. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 297-302.	1.3	9
62	Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections. <i>Clinical Infectious Diseases</i> , 2019, 68, 1335-1342.	5.8	61
63	Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial. <i>Lancet HIV</i> , 2019, 6, e498-e508.	4.7	35
64	Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study. <i>PLoS ONE</i> , 2019, 14, e0221281.	2.5	24
65	Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1395-1401.	3.0	14
66	Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 788-793.	1.1	8
67	Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2360-2364.	3.0	13
68	Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2352-2359.	3.0	9
69	Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1228-1233.	1.2	17
70	Engagement in Mental Health Care is Associated with Higher Cumulative Drug Exposure and Adherence to Antiretroviral Therapy. <i>AIDS and Behavior</i> , 2019, 23, 3493-3502.	2.7	16
71	Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV. <i>Journal of Infectious Diseases</i> , 2019, 220, 635-642.	4.0	43
72	Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV. <i>Journal of the International Association of Providers of AIDS Care</i> , 2019, 18, 232595821988845.	1.5	17

#	ARTICLE	IF	CITATIONS
73	Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, 158-162.	2.1	16
74	Predictors of Long-Term HIV Pre-exposure Prophylaxis Adherence After Study Participation in Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, 166-174.	2.1	15
75	The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. <i>Aids</i> , 2019, 33, 237-246.	2.2	17
76	Self-initiated continuation of and adherence to HIV pre-exposure prophylaxis (PrEP) after PrEP demonstration project roll-off in men who have sex with men: associations with risky decision making, impulsivity/disinhibition, and sensation seeking. <i>Journal of NeuroVirology</i> , 2019, 25, 324-330.	2.1	11
77	Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. <i>Lancet HIV,the</i> , 2019, 6, e43-e50.	4.7	43
78	Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 123-128.	1.1	7
79	Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 2010-2017.	5.8	96
80	Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048. <i>Clinical Infectious Diseases</i> , 2019, 68, 1129-1135.	5.8	14
81	Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings. <i>Clinical Infectious Diseases</i> , 2019, 68, 1136-1143.	5.8	22
82	Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. <i>Lancet HIV,the</i> , 2018, 5, e136-e145.	4.7	130
83	Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. <i>Clinical Infectious Diseases</i> , 2018, 67, 411-419.	5.8	50
84	Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 1712-1721.	5.8	48
85	Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States. <i>Clinical Infectious Diseases</i> , 2018, 66, 213-219.	5.8	82
86	Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. <i>Lancet HIV,the</i> , 2018, 5, e68-e78.	4.7	96
87	Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 193-198.	2.1	35
88	Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 295-298.	2.1	23
89	Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	182
90	Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine. <i>Aids</i> , 2018, 32, 2189-2194.	2.2	14

#	ARTICLE	IF	CITATIONS
91	Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1. <i>Emerging Infectious Diseases</i> , 2018, 24, .	4.3	38
92	What Can Urine Tell Us About Medication Adherence?. <i>EClinicalMedicine</i> , 2018, 2-3, 5-6.	7.1	11
93	Pharmacologic-Based Methods of Adherence Assessment in HIV Prevention. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1056-1059.	4.7	29
94	Cryopreservation of human mucosal tissues. <i>PLoS ONE</i> , 2018, 13, e0200653.	2.5	14
95	Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 835-837.	1.1	12
96	In-capillary microextraction for direct mass spectrometry analysis of biological samples. <i>Talanta</i> , 2018, 189, 451-457.	5.5	15
97	Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2112-2119.	3.0	15
98	Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis. <i>Journal of Controlled Release</i> , 2018, 286, 315-325.	9.9	66
99	Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	3
100	Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis. <i>Aids</i> , 2018, 32, 1891-1898.	2.2	31
101	Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial. <i>PLoS ONE</i> , 2018, 13, e0190118.	2.5	18
102	Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis. <i>New England Journal of Medicine</i> , 2017, 376, 501-502.	27.0	97
103	Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 271-279.	2.1	40
104	Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users. <i>Aids</i> , 2017, 31, 1709-1714.	2.2	103
105	Inflammation and pharmacokinetics: potential implications for HIV-infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 641-650.	3.3	24
106	Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 501-511.	2.1	60
107	Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. <i>Aids</i> , 2017, 31, 2245-2251.	2.2	47
108	Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, e104-e106.	2.1	64

#	ARTICLE	IF	CITATIONS
109	Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. <i>Lancet HIV</i> , 2017, 4, e522-e528.	4.7	69
110	Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 177-182.	2.1	25
111	Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2017, 64, 317-325.	5.8	54
112	Development and validation of an LC-MS/MS quantitative method for endogenous deoxynucleoside triphosphates in cellular lysate. <i>Biomedical Chromatography</i> , 2017, 31, e3820.	1.7	5
113	Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 478-485.	3.0	37
114	A LC-MS/MS Method for Quantifying Adenosine, Guanosine and Inosine Nucleotides in Human Cells. <i>Pharmaceutical Research</i> , 2017, 34, 73-83.	3.5	22
115	High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project. <i>Journal of the International AIDS Society</i> , 2017, 20, 21472.	3.0	98
116	Nondaily preexposure prophylaxis for HIV prevention. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 94-101.	3.8	36
117	A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring. <i>Aids</i> , 2016, 30, 743-751.	2.2	27
118	Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfecting patients with incomplete hepatitis B virus viral suppression. <i>Hepatology</i> , 2016, 64, 999-1000.	7.3	3
119	Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 122, 16-20.	2.8	100
120	Pharmacology supports on-demand PrEP. <i>Lancet HIV</i> , 2016, 3, e405-e406.	4.7	17
121	Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression. <i>Clinical Infectious Diseases</i> , 2016, 63, 1661-1667.	5.8	78
122	Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5387-5392.	3.2	11
123	Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 981-991.	1.1	66
124	Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6692-6697.	3.2	59
125	Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S230-S234.	2.1	17
126	Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. <i>Clinical Infectious Diseases</i> , 2016, 62, 1172-1177.	5.8	40

#	ARTICLE	IF	CITATIONS
127	Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1609-1618.	3.0	11
128	Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. <i>JAMA Internal Medicine</i> , 2016, 176, 75.	5.1	535
129	Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 32-43.	1.1	148
130	Measuring glomerular filtration rate by iohexol clearance on filter paper is feasible in adolescents with type 1 diabetes in the ambulatory setting. <i>Acta Diabetologica</i> , 2016, 53, 331-333.	2.5	8
131	Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates. <i>PLoS ONE</i> , 2016, 11, e0165505.	2.5	10
132	Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1015-1022.	1.1	1
133	Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir. <i>Journal of Infectious Diseases</i> , 2015, 212, 1988-1995.	4.0	26
134	Measurement of intracellular ribavirin mono-, di- and triphosphate using solid phase extraction and LC-MS/MS quantification. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 978-979, 163-172.	2.3	24
135	Population Pharmacokinetic Modeling of Plasma and Intracellular Ribavirin Concentrations in Patients with Chronic Hepatitis C Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2179-2188.	3.2	28
136	Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 61, 572-580.	5.8	132
137	Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. <i>Journal of Infectious Diseases</i> , 2015, 212, 1402-1406.	4.0	62
138	Dose Response for Starting and Stopping HIV Preexposure Prophylaxis for Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2015, 60, 804-810.	5.8	53
139	Reduced Immune Activation During Tenofovir-Emtricitabine Therapy in HIV-Negative Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 495-501.	2.1	19
140	Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 13-20.	2.1	72
141	Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7671-7679.	3.2	30
142	Short Communication: Tenofovir Diphosphate in Dried Blood Spots As an Objective Measure of Adherence in HIV-Infected Women. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 428-432.	1.1	35
143	Strong Relationship between Oral Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-Exposure Prophylaxis (PrEP). <i>PLoS ONE</i> , 2014, 9, e83736.	2.5	125
144	Patterns and Correlates of PrEP Drug Detection Among MSM and Transgender Women in the Global iPrEx Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 528-537.	2.1	63

#	ARTICLE	IF	CITATIONS
145	Study Product Adherence Measurement in the iPrEx Placebo-Controlled Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 66, 530-537.	2.1	73
146	Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2470-2476.	3.0	19
147	Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 88, 144-151.	2.8	51
148	Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 820-829.	9.1	1,039
149	Development and validation of a dried blood spot assay for the quantification of ribavirin using liquid chromatography coupled to mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 944, 18-24.	2.3	25
150	Validation of a sensitive LC/MS/MS method for the determination of telaprevir and its <i>trans</i> -isomer in human plasma. <i>Biomedical Chromatography</i> , 2014, 28, 1714-1721.	1.7	2
151	HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial. <i>Journal of Infectious Diseases</i> , 2014, 210, 1217-1227.	4.0	68
152	Clinical pharmacokinetics of antiretroviral drugs in older persons. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 573-588.	3.3	35
153	Tenofovir, Emtricitabine, and Tenofovir Diphosphate in Dried Blood Spots for Determining Recent and Cumulative Drug Exposure. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 384-390.	1.1	257
154	Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. <i>Science Translational Medicine</i> , 2012, 4, 151ra125.	12.4	807
155	Effect of HIV-1 Infection and Sex on the Cellular Pharmacology of the Antiretroviral Drugs Zidovudine and Lamivudine. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3011-3019.	3.2	12
156	Validation of a sensitive LC/MS/MS method for the determination of zidovudine and lamivudine in human plasma. <i>Biomedical Chromatography</i> , 2012, 26, 12-20.	1.7	18
157	A Population Pharmacokinetic-Pharmacogenetic Analysis of Atazanavir. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1227-1234.	1.1	39
158	Review and management of drug interactions with boceprevir and telaprevir. <i>Hepatology</i> , 2012, 55, 1620-1628.	7.3	123
159	Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 56, 390-401.	2.8	97
160	Effect of Nucleoside and Nucleotide Analog Reverse Transcriptase Inhibitors on Cell-Mediated Immune Functions. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 47-55.	1.1	13
161	Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 240-250.	3.0	159
162	Atazanavir Metabolism According to CYP3A5 Status: An In Vitro-In Vivo Assessment. <i>Drug Metabolism and Disposition</i> , 2011, 39, 522-527.	3.3	27

#	ARTICLE	IF	CITATIONS
163	Effect of Antacids on the Pharmacokinetics of Raltegravir in Human Immunodeficiency Virus-Seronegative Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4999-5003.	3.2	49
164	Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. <i>New England Journal of Medicine</i> , 2010, 363, 2587-2599.	27.0	4,268
165	Zidovudine and Lamivudine for HIV Infection. <i>Clinical Medicine Reviews in Therapeutics</i> , 2010, 2, a2004.	0.2	15
166	Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 1071-1079.	3.0	46
167	Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. <i>Aids</i> , 2009, 23, 1035-1046.	2.2	121
168	Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 738-745.	3.0	9
169	Clinical and Genetic Determinants of Intracellular Tenofovir Diphosphate Concentrations in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 47, 298-303.	2.1	143
170	Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 258-265.	3.8	8
171	Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults. <i>Aids</i> , 2007, 21, 1849-1854.	2.2	27
172	Pharmacogenetic Characteristics of Indinavir, Zidovudine, and Lamivudine Therapy in HIV-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 42, 441-449.	2.1	146
173	Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectrometry; an indirect quantitation methodology. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 831, 248-257.	2.3	42
174	Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 843, 147-156.	2.3	71
175	Comment on: Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 220-221.	3.0	6
176	Therapeutic drug monitoring: Pharmacologic considerations for antiretroviral drugs. <i>Current HIV/AIDS Reports</i> , 2005, 2, 61-67.	3.1	2
177	Stability of zidovudine with oxytocin in a simulated Y-site injection. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 394-396.	1.0	0
178	Reply to Stevens et al. <i>Clinical Infectious Diseases</i> , 2004, 39, 878-879.	5.8	4
179	The Cellular Pharmacology of Nucleoside- and Nucleotide-Analogue Reverse-Transcriptase Inhibitors and Its Relationship to Clinical Toxicities. <i>Clinical Infectious Diseases</i> , 2004, 38, 743-753.	5.8	127
180	Pharmacologic Perspectives for Once-Daily Antiretroviral Therapy. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1924-1934.	1.9	14

#	ARTICLE	IF	CITATIONS
181	Updated clinical pharmacologic considerations for HIV-1 protease inhibitors. <i>Current HIV/AIDS Reports</i> , 2004, 1, 33-39.	3.1	4
182	CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. <i>Aids</i> , 2004, 18, 2442-4.	2.2	19
183	Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. <i>Aids</i> , 2003, 17, 2159-2168.	2.2	121
184	Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. <i>Aids</i> , 2002, 16, 551-560.	2.2	133
185	CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 280-285.	4.7	12
186	Clinical pharmacologic considerations for HIV-1 protease inhibitors. <i>Current Infectious Disease Reports</i> , 2001, 3, 381-387.	3.0	13
187	Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine, and Indinavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 236-242.	3.2	62
188	Indinavir plasma protein binding in HIV-1-infected adults. <i>Aids</i> , 2000, 14, 2293-2297.	2.2	56
189	Zidovudine triphosphate and lamivudine triphosphate concentrationâ€“response relationships in HIV-infected persons. <i>Aids</i> , 2000, 14, 2137-2144.	2.2	103
190	Pharmacodynamics of Human Immunodeficiency Virus Type 1 Protease Inhibitors. <i>Clinical Infectious Diseases</i> , 2000, 30, S151-S159.	5.8	103
191	A Risk-Benefit Evaluation of Aciclovir for the Treatment and Prophylaxis of Herpes Simplex Virus Infections. <i>Drug Safety</i> , 2000, 23, 131-142.	3.2	30
192	Cumulative tenofovir diphosphate exposure in persons with <sc>HIV</sc> taking singleâ€“vs. multipleâ€“tablet regimens. <i>Pharmacotherapy</i> , 0, , .	2.6	1